Cellectar Biosciences Secures $140M, Pushes Iopofosine Toward FDA Filing
Cellectar Biosciences secured up to $140 million in new funding and reported strong Phase 2b results for iopofosine, fueling plans for a confirmatory trial and FDA filing in Waldenström macroglobulinemia.
Regulation
